Abstract
The aim of the present study was to determine whether alterations in 5-hydroxytryptamine (5-HT)1A receptors would be found in knockout mice lacking the serotonin transporter (5-HTT). Hypothermic and neuroendocrine responses to the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetraline (8-OH-DPAT) were used to examine the function of 5-HT1A receptors. Initial studies evaluated the dose-response and time course of 8-OH-DPAT-induced hypothermia and hormone secretion in normal CD-1 mice (the background strain of the 5-HTT knockout mice). 8-OH-DPAT dose-dependently produced hypothermic responses that peaked at 20 min postinjection. 8-OH-DPAT-induced hypothermia was blocked by the 5-HT1A antagonist WAY-100635. 8-OH-DPAT dose-dependently increased the concentrations of plasma oxytocin, corticotropin, and corticosterone. In the 5-HTT knockout (−/−) mice, the hypothermic response to 8-OH-DPAT (0.1 mg/kg s.c.) was completely abolished. Furthermore, 5-HTT−/− mice had significantly attenuated plasma oxytocin and corticosterone responses to 8-OH-DPAT. No significant changes in the hypothermic or hormonal responses to 8-OH-DPAT were observed in heterozygous (5-HTT+/−) mice. [3H]8-OH-DPAT- and [125I]MPPI [4-(2′-methoxyphenyl)-1-[2′-[N-(2"-pyridinyl)-iodobenzamido]ethyl]piperazine]-binding sites in the hypothalamus and [125I]MPPI-binding sites in the dorsal raphe were significantly decreased in 5-HTT−/− mice. The results indicate that lack of the 5-HTT is associated with a functional desensitization of 5-HT1A receptor responses to 8-OH-DPAT, which may be a consequence, at least in part, of the decrease in density of 5-HT1A receptors in the hypothalamus and dorsal raphe of 5-HTT−/− mice.
Footnotes
-
Send reprint requests to: Qian Li, Ph.D., Laboratory of Clinical Science, National Institute of Mental Health, National Institutes of Health Clinical Center, Room 3D41, 10 Center Dr., MSC-1264, Bethesda, MD 20892-1264. E-mail:qianli{at}codon.nih.gov
-
↵1 K.-P.L. is supported by the Hermann and Lilly Schilling Foundation.
- Abbreviations:
- 5-HT
- 5-hydroxytryptamine (serotonin)
- 5-HTT
- 5-hydroxytryptamine transporter
- 8-OH-DPAT
- 8-hydroxy-2-(di-n-propylamino)tetraline
- MPPI
- 4-(2′-methoxyphenyl)-1-[2′-[N-(2"-pyridinyl)-iodobenzamido]ethyl]piperazine
- WAY-100635
- (N-[2-(4(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-2-pyridyl)cyclohexanecarboxamide
- ACTH
- corticotropin
- SRI
- serotonin reuptake inhibitor
- Received March 26, 1999.
- Accepted August 7, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|